18.04.2019, 15:47
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California,
and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration
for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
WKN: 936718 / ISIN: US30161Q1040 Symbol: EXEL
![[Bild: chart.aspx?instruments=16,1069927,16,814...10a5c73b2f]](https://c.finanzen.net/cst/FinanzenDe/chart.aspx?instruments=16,1069927,16,814&style=snapshot_mountain_volume_oneyear_0digit&period=OneYear&hash=14b265118f7ec6dd5bbcad10a5c73b2f)
https://www.finanzen.net/aktien/Exelixis-Aktie
Ojay
and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration
for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
WKN: 936718 / ISIN: US30161Q1040 Symbol: EXEL
https://www.finanzen.net/aktien/Exelixis-Aktie
Ojay